Chemogenomic screening in patient-derived tissue models enables target identification and drug repurposing

The number of successful drug development projects has been stagnant for decades despite major breakthroughs in chemistry, molecular biology and genomics. Unreliable translatability of preclinical in vitro and in vivo models has been identified as the cause of most failure. Organotypic and microphysiological culture of primary human cells has emerged as a set of promising tools for preclinical drug development to narrow this translation gap. In this talk I will provide an overview of our recent efforts in developing 3D human tissue cultures and microfluidic models for both efficacy and safety assessments. In addition, the talk will present recent use cases where such organotypic cultures identified new drug targets and had direct impacts on market authorizations.

Content

Author and article information

Conference

Publisher: REPO4EU

Publication date (Electronic, pub): 4 October 2023

Affiliations

[1 ] Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (Sweden) ( https://ror.org/056d84691)

[2 ] Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart (Germany) ( https://ror.org/02pnjnj33)

[3 ] University of Tübingen, Tübingen (Germany) ( https://ror.org/03a1kwz48)

Author information

Volker M. Lauschke https://orcid.org/0000-0002-1140-6204

Article

DOI: 10.58647/REXPO.23017

SO-VID: add6b1a1-68c2-4670-9516-e490c268e518

License:

Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

Conference name: RExPO23

Conference number: 2

Conference location: Stockholm, Sweden

Conference date: 25-26 October 2023

History

Product

REPO4EU

References

Stebbing Justin, Lauschke Volker M.. JAK Inhibitors — More Than Just Glucocorticoids. New England Journal of Medicine. Vol. 385(5):463–465. 2021. Massachusetts Medical Society. [Cross Ref]

Comments

Comment on this article

[1] Stebbing Justin, Lauschke Volker M.. JAK Inhibitors — More Than Just Glucocorticoids. New England Journal of Medicine. Vol. 385(5):463–465. 2021. Massachusetts Medical Society. [Cross Ref]